Patrick A. M. Jansen

Patrick A. M. Jansen

Auto-generated profile, based on publicly available information

Patrick A. M. Jansen


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JSJoost Schalkwijk
Joost Schalkwijk
EAErik L. Allman
Erik L. Allman
PJPatrick A. M. Jansen
Patrick A. M. Jansen
LVLaura E. de Vries
Laura E. de Vries
JVJulie M. J. Verhoef
Julie M. J. Verhoef
KDKoen J. Dechering
Koen J. Dechering
Pantothenamides form antimetabolites that interfere with acetyl-CoA metabolism in the human malaria parasite Plasmodium falciparum.

7 March 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
JSJos Smits
Jos Smits
NBNoa J.M. van Den Brink
Noa J.M. van Den Brink
LMLuca D. Meesters
Luca D. Meesters
HHHadia Hamdaoui
Hadia Hamdaoui
HNHanna Niehues
Hanna Niehues
EBEllen H. van den Bogaard
Ellen H. van den Bogaard
Ever since the association between FLG loss-of-function variants and ichthyosis vulgaris and atopic dermatitis disease onset was identified, FLGs function has been under investigation. Intraindividual genomic predisposition, immunological confounders, and environmental interactions complicate the comparison between FLG genotypes and related causal effects. Using CRISPR/Cas9, we generated human FLG-knockout (ΔFLG) N/TERT-2G keratinocytes. FLG deficiency was shown by immunohistochemistry of human epidermal equivalent cultures. Next to (partial) loss of structural proteins (involucrin, hornerin, keratin 2, and transglutaminase 1), the stratum corneum was denser and lacked the typical basket weave appearance. In addition, electrical impedance spectroscopy and transepidermal water loss analyses highlighted a compromised epidermal barrier in ΔFLG human epidermal equivalents. Correction of FLG reinstated the presence of keratohyalin granules in the stratum granulosum, FLG protein expression, and expression of the proteins mentioned earlier. The beneficial effects on stratum corneum formation were reflected by the normalization of electrical impedance spectroscopy and transepidermal water loss. This study shows the causal phenotypical and functional consequences of FLG deficiency, indicating that FLG is not only central in epidermal barrier function but also vital for epidermal differentiation by orchestrating the expression of other important epidermal proteins. These observations pave the way to fundamental investigations into the exact role of FLG in skin biology and disease.

18 April 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
HPHelmi E Pett
Helmi E Pett
PJPatrick Am Jansen
Patrick Am Jansen
PHPedro Hh Hermkens
Pedro Hh Hermkens
PBPeter Nm Botman
Peter Nm Botman
CBChristien A Beuckens-Schortinghuis
Christien A Beuckens-Schortinghuis
JSJoost Schalkwijk
Joost Schalkwijk
A number of synthetic pantothenate derivatives, such as pantothenamides, are known to inhibit the growth of the human malaria parasite Plasmodium falciparum, by interfering with the parasite Coenzyme A (CoA) biosynthetic pathway. The clinical use of pantothenamides is limited by their sensitivity to breakdown by ubiquitous human pantetheinases of the vanin family. A number of pantothenate derivatives (pantothenones) with potent and specific inhibitory activity against mammalian vanins were tested in a proliferation assay of asexual P. falciparum blood stages alone, and in combination with pantothenamides. The vanin inhibitors were found to protect pantothenamides against breakdown by plasma vanins, thereby preserving the in vitro anti-malarial activity. Moreover, some of the vanin inhibitors showed in vitro anti-malarial activity in the low micromolar range. The most potent antimalarial in this series of compounds (RR8), was found to compete with pantothenate in a combination proliferation assay. No correlation, however, was found between anti-vanin and anti-malarial activity, nor was pantetheinase activity detected in P. falciparum extracts. Growth inhibition is most likely due to competition with pantothenate, rather than pantetheinase inhibition. As vanin inhibitors of the pantothenone class are stable in biological fluids and are non-toxic to mammalian cells, they may represent novel pantothenate-based anti-malarials, either on their own or in combination with pantothenamides.

6 June 2019 in The Journal of Antibiotics
Verified
Journal Article
Open access
PDF file
PJPatrick A. M. Jansen
Patrick A. M. Jansen
DKDanique A. van der Krieken
Danique A. van der Krieken
PBPeter N. M. Botman
Peter N. M. Botman
RBRichard H. Blaauw
Richard H. Blaauw
LCLorenzo Cavina
Lorenzo Cavina
JSJoost Schalkwijk
Joost Schalkwijk
The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis, but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future direction for the development of pantothenamides with clinical potential.

1 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
HNHanna Niehues
Hanna Niehues
DKDanique A. van der Krieken
Danique A. van der Krieken
TEThomas H.A. Ederveen
Thomas H.A. Ederveen
PJPatrick A.M. Jansen
Patrick A.M. Jansen
LNLaura van Niftrik
Laura van Niftrik
PZPatrick Zeeuwen
Patrick Zeeuwen
Late cornified envelope proteins are predominantly expressed in the skin and other cornified epithelia. On the basis of sequence similarity, this 18-member homologous gene family has been subdivided into six groups. The LCE3 proteins have been the focus of dermatological research because the combined deletion of LCE3B and LCE3C genes (LCE3B/C-del) is a risk factor for psoriasis. We previously reported that LCE3B/C-del increases the expression of the LCE3A gene and that LCE3 proteins exert antibacterial activity. In this study, we analyzed the antimicrobial properties of other family members and the role of LCE3B/C-del in the modulation of microbiota composition of the skin and oral cavity. Differences in killing efficiency and specificity between the late cornified envelope proteins and their target microbes were found, and the amino acid content rather than the order of the well-conserved central domain of the LCE3A protein was found responsible for its antibacterial activity. In vivo, LCE3B/C-del correlated with a higher beta-diversity in the skin and oral microbiota. From these results, we conclude that all late cornified envelope proteins possess antimicrobial activity. Tissue-specific and genotype-dependent antimicrobial protein profiles impact skin and oral microbiota composition, which could direct toward LCE3B/C-del‒associated dysbiosis and a possible role for microbiota in the pathophysiology of psoriasis.

13 November 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
NHNoor E van Hout
Noor E van Hout
GNGuillermo Nevot
Guillermo Nevot
PJPatrick A M Jansen
Patrick A M Jansen
AMAhmad A Mannan
Ahmad A Mannan
PZPatrick Zeeuwen
Patrick Zeeuwen
EBEllen H. van den Bogaard
Ellen H. van den Bogaard
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with diverse clinical and histological features. While primarily immune-mediated, genetic studies have also highlighted the role of epithelium-expressed gene abnormalities (e.g. FLG mutations) as a key factor. Approaches to treating AD are multifaceted, involving barrier restoration, local anti-inflammatory treatment and, if needed, systemic immunosuppressive therapy. Genetic variations in the stratum corneum and the immune system are linked to an imbalance between the host and its microbiota, known as dysbiosis. An impaired skin barrier and immune responses can alter the microbial composition, while the skin microbiota itself can influence skin immunity and barrier formation. A hallmark of AD is increased bacterial colonization with Staphylococcus aureus, which is found on lesional skin in > 90% of patients with AD. It contributes to disease severity by driving further breakdown of the skin barrier and immune stimulation. The most common treatments for S. aureus infections in AD are topical or systemic antibiotics. While these treatments are typically reserved for active infections, they are sometimes prescribed to patients with AD without a clear skin infection. These treatments can disrupt commensal skin and gut microbiota, which play a critical role in maintaining skin and gut health. In this review we describe various treatments that target the skin microbiome to reduce infection and inflammation in AD, including transplantation of microbiota, and the use of prebiotics, probiotics and postbiotics. In addition, we provide a perspective to engineer and harness bacteria of the skin microbiome as next-generation probiotics, also known as engineered live biotherapeutic products, using synthetic biology to create strains that can sense skin signals, such as immune signals, and environmental factors, and produce therapeutic treatments for AD on demand.